Global Dendritic Cell Cancer Vaccine Immunotherapy Market Research Report 2023
Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.
According to QYResearch’s new survey, global Dendritic Cell Cancer Vaccine Immunotherapy market is projected to reach US$ 1214.8 million in 2029, increasing from US$ 622 million in 2022, with the CAGR of 10.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dendritic Cell Cancer Vaccine Immunotherapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Dendritic Cell Cancer Vaccine Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Dendritic Cell Cancer Vaccine Immunotherapy market is projected to reach US$ 1214.8 million in 2029, increasing from US$ 622 million in 2022, with the CAGR of 10.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dendritic Cell Cancer Vaccine Immunotherapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Dendritic Cell Cancer Vaccine Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Lineage Cell Therapeutics
- AVAX Technologies
- DCPrime
- Gradalis
- Heat Biologics
- ImmunoCellular Therapeutics
- Immunicum
- MolecuVax
- Northwest Biotherapeutics
- Pique Therapeutics
- Regeneus
- Tessa Therapeutics
- Vaccinogen
- XEME Biopharma
- Provenge
- Apceden
- CreaVax
- Others
- Pediatrics
- Adults
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Provenge
1.2.3 Apceden
1.2.4 CreaVax
1.2.5 Others
1.3 Market by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2018-2029)
2.2 Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Region
2.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029)
2.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics
2.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
2.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
2.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
2.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue
3.1.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dendritic Cell Cancer Vaccine Immunotherapy Revenue
3.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio
3.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
3.5 Dendritic Cell Cancer Vaccine Immunotherapy Key Players Head office and Area Served
3.6 Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
3.7 Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY TYPE
4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029)
5 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
6.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
7.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
9.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
9.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Lineage Cell Therapeutics
11.1.1 Lineage Cell Therapeutics Company Detail
11.1.2 Lineage Cell Therapeutics Business Overview
11.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.1.4 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.1.5 Lineage Cell Therapeutics Recent Development
11.2 AVAX Technologies
11.2.1 AVAX Technologies Company Detail
11.2.2 AVAX Technologies Business Overview
11.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.2.4 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.2.5 AVAX Technologies Recent Development
11.3 DCPrime
11.3.1 DCPrime Company Detail
11.3.2 DCPrime Business Overview
11.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.3.4 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.3.5 DCPrime Recent Development
11.4 Gradalis
11.4.1 Gradalis Company Detail
11.4.2 Gradalis Business Overview
11.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.4.4 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.4.5 Gradalis Recent Development
11.5 Heat Biologics
11.5.1 Heat Biologics Company Detail
11.5.2 Heat Biologics Business Overview
11.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.5.4 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.5.5 Heat Biologics Recent Development
11.6 ImmunoCellular Therapeutics
11.6.1 ImmunoCellular Therapeutics Company Detail
11.6.2 ImmunoCellular Therapeutics Business Overview
11.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.6.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.6.5 ImmunoCellular Therapeutics Recent Development
11.7 Immunicum
11.7.1 Immunicum Company Detail
11.7.2 Immunicum Business Overview
11.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.7.4 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.7.5 Immunicum Recent Development
11.8 MolecuVax
11.8.1 MolecuVax Company Detail
11.8.2 MolecuVax Business Overview
11.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.8.4 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.8.5 MolecuVax Recent Development
11.9 Northwest Biotherapeutics
11.9.1 Northwest Biotherapeutics Company Detail
11.9.2 Northwest Biotherapeutics Business Overview
11.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.9.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.9.5 Northwest Biotherapeutics Recent Development
11.10 Pique Therapeutics
11.10.1 Pique Therapeutics Company Detail
11.10.2 Pique Therapeutics Business Overview
11.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.10.4 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.10.5 Pique Therapeutics Recent Development
11.11 Regeneus
11.11.1 Regeneus Company Detail
11.11.2 Regeneus Business Overview
11.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.11.4 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.11.5 Regeneus Recent Development
11.12 Tessa Therapeutics
11.12.1 Tessa Therapeutics Company Detail
11.12.2 Tessa Therapeutics Business Overview
11.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.12.4 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.12.5 Tessa Therapeutics Recent Development
11.13 Vaccinogen
11.13.1 Vaccinogen Company Detail
11.13.2 Vaccinogen Business Overview
11.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.13.4 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.13.5 Vaccinogen Recent Development
11.14 XEME Biopharma
11.14.1 XEME Biopharma Company Detail
11.14.2 XEME Biopharma Business Overview
11.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.14.4 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.14.5 XEME Biopharma Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Provenge
1.2.3 Apceden
1.2.4 CreaVax
1.2.5 Others
1.3 Market by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2018-2029)
2.2 Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Region
2.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029)
2.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics
2.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
2.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
2.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
2.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue
3.1.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dendritic Cell Cancer Vaccine Immunotherapy Revenue
3.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio
3.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
3.5 Dendritic Cell Cancer Vaccine Immunotherapy Key Players Head office and Area Served
3.6 Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
3.7 Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY TYPE
4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029)
5 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
6.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
7.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
9.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
9.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Lineage Cell Therapeutics
11.1.1 Lineage Cell Therapeutics Company Detail
11.1.2 Lineage Cell Therapeutics Business Overview
11.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.1.4 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.1.5 Lineage Cell Therapeutics Recent Development
11.2 AVAX Technologies
11.2.1 AVAX Technologies Company Detail
11.2.2 AVAX Technologies Business Overview
11.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.2.4 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.2.5 AVAX Technologies Recent Development
11.3 DCPrime
11.3.1 DCPrime Company Detail
11.3.2 DCPrime Business Overview
11.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.3.4 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.3.5 DCPrime Recent Development
11.4 Gradalis
11.4.1 Gradalis Company Detail
11.4.2 Gradalis Business Overview
11.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.4.4 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.4.5 Gradalis Recent Development
11.5 Heat Biologics
11.5.1 Heat Biologics Company Detail
11.5.2 Heat Biologics Business Overview
11.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.5.4 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.5.5 Heat Biologics Recent Development
11.6 ImmunoCellular Therapeutics
11.6.1 ImmunoCellular Therapeutics Company Detail
11.6.2 ImmunoCellular Therapeutics Business Overview
11.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.6.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.6.5 ImmunoCellular Therapeutics Recent Development
11.7 Immunicum
11.7.1 Immunicum Company Detail
11.7.2 Immunicum Business Overview
11.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.7.4 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.7.5 Immunicum Recent Development
11.8 MolecuVax
11.8.1 MolecuVax Company Detail
11.8.2 MolecuVax Business Overview
11.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.8.4 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.8.5 MolecuVax Recent Development
11.9 Northwest Biotherapeutics
11.9.1 Northwest Biotherapeutics Company Detail
11.9.2 Northwest Biotherapeutics Business Overview
11.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.9.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.9.5 Northwest Biotherapeutics Recent Development
11.10 Pique Therapeutics
11.10.1 Pique Therapeutics Company Detail
11.10.2 Pique Therapeutics Business Overview
11.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.10.4 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.10.5 Pique Therapeutics Recent Development
11.11 Regeneus
11.11.1 Regeneus Company Detail
11.11.2 Regeneus Business Overview
11.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.11.4 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.11.5 Regeneus Recent Development
11.12 Tessa Therapeutics
11.12.1 Tessa Therapeutics Company Detail
11.12.2 Tessa Therapeutics Business Overview
11.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.12.4 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.12.5 Tessa Therapeutics Recent Development
11.13 Vaccinogen
11.13.1 Vaccinogen Company Detail
11.13.2 Vaccinogen Business Overview
11.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.13.4 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.13.5 Vaccinogen Recent Development
11.14 XEME Biopharma
11.14.1 XEME Biopharma Company Detail
11.14.2 XEME Biopharma Business Overview
11.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.14.4 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
11.14.5 XEME Biopharma Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Provenge
Table 3. Key Players of Apceden
Table 4. Key Players of CreaVax
Table 5. Key Players of Others
Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2023)
Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2024-2029)
Table 12. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
Table 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
Table 14. Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
Table 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players (2018-2023)
Table 18. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
Table 19. Ranking of Global Top Dendritic Cell Cancer Vaccine Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
Table 23. Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2018-2023)
Table 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2024-2029)
Table 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2018-2023)
Table 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2024-2029)
Table 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 48. Lineage Cell Therapeutics Company Detail
Table 49. Lineage Cell Therapeutics Business Overview
Table 50. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 51. Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 52. Lineage Cell Therapeutics Recent Development
Table 53. AVAX Technologies Company Detail
Table 54. AVAX Technologies Business Overview
Table 55. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 56. AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 57. AVAX Technologies Recent Development
Table 58. DCPrime Company Detail
Table 59. DCPrime Business Overview
Table 60. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 61. DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 62. DCPrime Recent Development
Table 63. Gradalis Company Detail
Table 64. Gradalis Business Overview
Table 65. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 66. Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 67. Gradalis Recent Development
Table 68. Heat Biologics Company Detail
Table 69. Heat Biologics Business Overview
Table 70. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 71. Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 72. Heat Biologics Recent Development
Table 73. ImmunoCellular Therapeutics Company Detail
Table 74. ImmunoCellular Therapeutics Business Overview
Table 75. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 76. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 77. ImmunoCellular Therapeutics Recent Development
Table 78. Immunicum Company Detail
Table 79. Immunicum Business Overview
Table 80. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 81. Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 82. Immunicum Recent Development
Table 83. MolecuVax Company Detail
Table 84. MolecuVax Business Overview
Table 85. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 86. MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 87. MolecuVax Recent Development
Table 88. Northwest Biotherapeutics Company Detail
Table 89. Northwest Biotherapeutics Business Overview
Table 90. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 91. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 92. Northwest Biotherapeutics Recent Development
Table 93. Pique Therapeutics Company Detail
Table 94. Pique Therapeutics Business Overview
Table 95. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 96. Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 97. Pique Therapeutics Recent Development
Table 98. Regeneus Company Detail
Table 99. Regeneus Business Overview
Table 100. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 101. Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 102. Regeneus Recent Development
Table 103. Tessa Therapeutics Company Detail
Table 104. Tessa Therapeutics Business Overview
Table 105. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 106. Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 107. Tessa Therapeutics Recent Development
Table 108. Vaccinogen Company Detail
Table 109. Vaccinogen Business Overview
Table 110. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 111. Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 112. Vaccinogen Recent Development
Table 113. XEME Biopharma Company Detail
Table 114. XEME Biopharma Business Overview
Table 115. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 116. XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 117. XEME Biopharma Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Provenge
Table 3. Key Players of Apceden
Table 4. Key Players of CreaVax
Table 5. Key Players of Others
Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2023)
Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2024-2029)
Table 12. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
Table 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
Table 14. Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
Table 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players (2018-2023)
Table 18. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
Table 19. Ranking of Global Top Dendritic Cell Cancer Vaccine Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
Table 23. Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2018-2023)
Table 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2024-2029)
Table 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2018-2023)
Table 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2024-2029)
Table 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 48. Lineage Cell Therapeutics Company Detail
Table 49. Lineage Cell Therapeutics Business Overview
Table 50. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 51. Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 52. Lineage Cell Therapeutics Recent Development
Table 53. AVAX Technologies Company Detail
Table 54. AVAX Technologies Business Overview
Table 55. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 56. AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 57. AVAX Technologies Recent Development
Table 58. DCPrime Company Detail
Table 59. DCPrime Business Overview
Table 60. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 61. DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 62. DCPrime Recent Development
Table 63. Gradalis Company Detail
Table 64. Gradalis Business Overview
Table 65. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 66. Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 67. Gradalis Recent Development
Table 68. Heat Biologics Company Detail
Table 69. Heat Biologics Business Overview
Table 70. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 71. Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 72. Heat Biologics Recent Development
Table 73. ImmunoCellular Therapeutics Company Detail
Table 74. ImmunoCellular Therapeutics Business Overview
Table 75. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 76. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 77. ImmunoCellular Therapeutics Recent Development
Table 78. Immunicum Company Detail
Table 79. Immunicum Business Overview
Table 80. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 81. Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 82. Immunicum Recent Development
Table 83. MolecuVax Company Detail
Table 84. MolecuVax Business Overview
Table 85. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 86. MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 87. MolecuVax Recent Development
Table 88. Northwest Biotherapeutics Company Detail
Table 89. Northwest Biotherapeutics Business Overview
Table 90. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 91. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 92. Northwest Biotherapeutics Recent Development
Table 93. Pique Therapeutics Company Detail
Table 94. Pique Therapeutics Business Overview
Table 95. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 96. Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 97. Pique Therapeutics Recent Development
Table 98. Regeneus Company Detail
Table 99. Regeneus Business Overview
Table 100. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 101. Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 102. Regeneus Recent Development
Table 103. Tessa Therapeutics Company Detail
Table 104. Tessa Therapeutics Business Overview
Table 105. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 106. Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 107. Tessa Therapeutics Recent Development
Table 108. Vaccinogen Company Detail
Table 109. Vaccinogen Business Overview
Table 110. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 111. Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 112. Vaccinogen Recent Development
Table 113. XEME Biopharma Company Detail
Table 114. XEME Biopharma Business Overview
Table 115. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 116. XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US$ Million)
Table 117. XEME Biopharma Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type: 2022 VS 2029
Figure 3. Provenge Features
Figure 4. Apceden Features
Figure 5. CreaVax Features
Figure 6. Others Features
Figure 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2022 VS 2029
Figure 9. Pediatrics Case Studies
Figure 10. Adults Case Studies
Figure 11. Dendritic Cell Cancer Vaccine Immunotherapy Report Years Considered
Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region: 2022 VS 2029
Figure 15. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players in 2022
Figure 16. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
Figure 18. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 20. United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 24. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2029)
Figure 32. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 40. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 44. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Lineage Cell Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 47. AVAX Technologies Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 48. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 49. Gradalis Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 50. Heat Biologics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 51. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 52. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 53. MolecuVax Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 54. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 55. Pique Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 56. Regeneus Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 57. Tessa Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 58. Vaccinogen Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 59. XEME Biopharma Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Figure 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type: 2022 VS 2029
Figure 3. Provenge Features
Figure 4. Apceden Features
Figure 5. CreaVax Features
Figure 6. Others Features
Figure 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2022 VS 2029
Figure 9. Pediatrics Case Studies
Figure 10. Adults Case Studies
Figure 11. Dendritic Cell Cancer Vaccine Immunotherapy Report Years Considered
Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region: 2022 VS 2029
Figure 15. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players in 2022
Figure 16. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
Figure 18. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 20. United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 24. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2029)
Figure 32. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 40. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
Figure 44. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Lineage Cell Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 47. AVAX Technologies Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 48. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 49. Gradalis Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 50. Heat Biologics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 51. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 52. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 53. MolecuVax Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 54. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 55. Pique Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 56. Regeneus Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 57. Tessa Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 58. Vaccinogen Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 59. XEME Biopharma Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
